[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100436312":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Children's Hospital of Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group",null,"Children treated with caspofungin in the pediatric intensive care unit",[13],"Drug: Caspofungin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Caspofungin","For children 3 months of age, the recommended dose is 70 mg\u002Fm2 for load and then 50 mg\u002Fm2 for maintenance, intravenous injection, once daily up to 5 days.",[9],[21],{"name":22,"affiliation":5,"role":23},"Guoping Lu, doctor","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Yixue Wang, doctor","CONTACT","8613524669352","yixuewang08@aliyun.com",[31,49],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Shanghai","Shanghai Municipality","201102","China","CN",{"type":39,"coordinates":40},"Point",[41,42],121.45806,31.22222,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":10,"email":48},"Guoping Lu, PhD","18017590817","13788904150@163.com",{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":50,"geoPoint":52,"contacts":10},{"type":39,"coordinates":51},[41,42],{"lat":42,"lon":41},{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100436312","pkpd-of-caspofungin-in-children-severe-infection-100436312",false,"NCT04961593","PK\u002FPD of Caspofungin in Children Severe Infection","Pharmacokinetics and Pharmacodynamics of Caspofungin in Children Severe Infection","Inclusion Criteria:\n\n* Children receiving caspofungin in pediatric intensive care unit\n\nExclusion Criteria:\n\n* No Informed Consent signed Participate in other clinical trials","ALL","3 Months","18 Years",{"count":66,"type":67},60,"ESTIMATED","OBSERVATIONAL","Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. There is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. The study aim to investigate PK\u002FPD of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ECMO treatment, or sepsis.",[71,72],"Pharmacokinetics","Infection, Fungal","2026-02-12",{"date":75,"type":76},"2026-02-17","ACTUAL",{"date":78,"type":76},"2022-10-01",{"date":80,"type":67},"2026-12-01",{"name":5,"class":6},2]